JY
VBIV

Jeff Yass’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Jeff Yass’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,725
Closed -$41.9K – 13236
2023
Q2 		$41.9K Buy
12,725
+5,948
+88% +$18K ﹤0.01% 11398
2023
Q1 		$61.6K Buy
6,777
+258
+4% +$3.65K ﹤0.01% 11600
2022
Q4 		$76.5K Sell
6,519
-783
-11% -$13.8K ﹤0.01% 11169
2022
Q3 		$155K Sell
7,302
-3,679
-34% -$99.2K ﹤0.01% 11192
2022
Q2 		$266K Sell
10,981
-2,843
-21% -$96.7K ﹤0.01% 9889
2022
Q1 		$688K Sell
13,824
-27,664
-67% -$1.37M ﹤0.01% 8129
2021
Q4 		$2.91M Buy
41,488
+18,888
+84% +$1.59M ﹤0.01% 4699
2021
Q3 		$2.11M Sell
22,600
-32,078
-59% -$3.05M ﹤0.01% 5714
2021
Q2 		$5.5M Sell
54,678
-6,181
-10% -$602K ﹤0.01% 3876
2021
Q1 		$5.68M Buy
60,859
+17,743
+41% +$1.8M ﹤0.01% 3664
2020
Q4 		$3.56M Buy
43,116
+10,288
+31% +$877K ﹤0.01% 4014
2020
Q3 		$2.82M Buy
32,828
+17,931
+120% +$2.09M ﹤0.01% 3983
2020
Q2 		$1.39M Buy
14,897
+1,653
+12% +$91.1K ﹤0.01% 5194
2020
Q1 		$377K Buy
13,244
+8,640
+188% +$336K ﹤0.01% 7537
2019
Q4 		$191K Buy
4,604
+3,066
+199% +$67.1K ﹤0.01% 8799
2019
Q3 		$22K Sell
1,538
-119
-7% -$2.49K ﹤0.01% 9939
2019
Q2 		$58K Buy
+1,657
New +$89.8K ﹤0.01% 9809
2018
Q4 		– Sell
-449
Closed -$33K – 10174
2018
Q3 		$33K Sell
449
-102
-19% -$6.73K ﹤0.01% 8925
2018
Q2 		$45K Buy
+551
New +$53.2K ﹤0.01% 9304
2017
Q2 		– Sell
-3,994
Closed -$658K – 9975
2017
Q1 		$658K Buy
3,994
+3,640
+1,028% +$493K ﹤0.01% 5978
2016
Q4 		$33K Buy
+354
New +$33.8K ﹤0.01% 9366

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jeff Yass's VBIV Position: Q3 2023 in Review

Jeff Yass sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2023, closing a stake of 12,725 shares — an estimated $41.9K sold.

Jeff Yass first reported a position in VBIV in Q4 2016 and held it in 21 quarters. The position peaked at $5.68M in Q1 2021. 37 funds tracked by Wall St. Rank hold VBIV as of Q3 2023.

  • Jeff Yass reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2023 after selling out during the quarter.
  • Jeff Yass sold 12,725 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2023, an estimated $41.9K.
  • Jeff Yass first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2016 and held it in 21 quarters.
  • Jeff Yass's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $5.68M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.